Zoetis Inc. (NYSE:ZTS) Shares Sold by William Allan Corp

William Allan Corp cut its holdings in Zoetis Inc. (NYSE:ZTS) by 46.7% in the 4th quarter, HoldingsChannel reports. The fund owned 15,410 shares of the company’s stock after selling 13,482 shares during the period. Zoetis makes up 1.5% of William Allan Corp’s investment portfolio, making the stock its 27th largest position. William Allan Corp’s holdings in Zoetis were worth $2,511,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of ZTS. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the 3rd quarter valued at $33,000. Dunhill Financial LLC grew its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. Finally, Fortitude Family Office LLC grew its stake in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Morgan Stanley decreased their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $215.00.

Zoetis Stock Performance

Shares of Zoetis stock opened at $174.07 on Friday. The firm has a market cap of $78.54 billion, a PE ratio of 32.72, a price-to-earnings-growth ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The firm’s 50-day simple moving average is $169.39 and its 200-day simple moving average is $179.32. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.36 earnings per share. Equities analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.15%. Zoetis’s dividend payout ratio is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.